Lasca (Dienogest, Ethinylestradiol)

The ethinylestradiol component provides estrogenic activity that stabilises the endometrial lining, while dienogest, a progestogen, suppresses the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). This dual action blocks ovulation and alters cervical mucus and the uterine lining, reducing the chance of fertilisation and implantation.

The dosing regimen is determined by the prescribing clinician. Typically, Lasca is taken as one tablet daily for a set number of days followed by a pill‑free interval, but the exact schedule and any variations are individualized based on the patient’s medical history and the prescriber’s judgment.

Lasca is not intended for use during pregnancy and should be discontinued if pregnancy occurs. Limited safety data exist for breastfeeding; generally, combined oral contraceptives are not recommended for nursing mothers unless the benefits outweigh potential risks, and the prescriber should evaluate each case.

To order Lasca, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lasca offers efficacy comparable to other combined oral contraceptives. Its progestogen component, dienogest, has lower androgenic activity than some older progestins, which may result in a more favourable side‑effect profile for acne or lipid metabolism, while still providing reliable contraception.

Store Lasca tablets at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack or container, protect it from moisture and direct light, and ensure the packaging remains sealed until use to maintain potency.

Lasca is taken orally as a tablet with water. It is usually recommended to take the tablet at the same time each day to maintain consistent hormone levels, and patients should follow the schedule prescribed by their healthcare professional.

The most serious risks include venous or arterial thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, or myocardial infarction. Additional concerns are severe hypertension, liver disorders, and rare but potentially life‑threatening allergic reactions. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.

Lasca is contraindicated in women with a history of thromboembolic disease, uncontrolled hypertension, known estrogen‑dependent tumours, severe liver disease, or those who smoke cigarettes and are over 35 years of age. It should also be avoided in individuals with known hypersensitivity to dienogest, ethinylestradiol, or any excipients in the tablet.